. Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. J. Appl. Physiol. 87(2): 809-816, 1999.-Patients with peripheral arterial disease (PAD) have arterial occlusions that limit peripheral blood flow. This study evaluated the dynamic response in O 2 consumption (V O 2 ) at the onset of constant-load exercise (V O 2 kinetics) in patients with PAD. Eight patients with bilateral PAD, seven patients with unilateral PAD, nine age-matched nonsmoking controls, and seven smoking controls performed graded treadmill exercise to assess peak V O 2 . Subjects also performed constant-load exercise tests at 2.0 miles/h at 0 and 4% grade to determine V O 2 kinetics. Peak V O 2 was reduced 50% in patients with PAD compared with both control groups (P Ͻ 0.05). At 4% grade, phase 2 V O 2 kinetics were significantly slowed for the PAD groups compared with controls (60.1 Ϯ 15.7 and 58.7 Ϯ 8.3 s, unilateral and bilateral PAD groups, respectively; compared with 28.4 Ϯ 19.3 and 27.9 Ϯ 8.1 s, nonsmoking and smoking controls, respectively; P Ͻ 0.05). No relationship was found between V O 2 kinetics and disease severity. These data demonstrate that V O 2 kinetics are markedly slowed in patients with PAD. The impairment in V O 2 kinetics is not related to smoking status or arterial disease severity and therefore may reflect altered control of skeletal muscle metabolism. heart rate; oxygen consumption; muscle metabolism WITH THE TRANSITION from rest to constant-load exercise, the rate of change in O 2 uptake (V O 2 kinetics) reflects the ability of the cardiopulmonary system to deliver O 2 , as well as the rate at which O 2 is taken up and utilized by exercising skeletal muscle. Changes in V O 2 kinetics with disease may provide insight into the alterations in physiological regulation that are associated with an impairment in exercise performance and functional capacity.
WITH THE TRANSITION from rest to constant-load exercise, the rate of change in O 2 uptake (V O 2 kinetics) reflects the ability of the cardiopulmonary system to deliver O 2 , as well as the rate at which O 2 is taken up and utilized by exercising skeletal muscle. Changes in V O 2 kinetics with disease may provide insight into the alterations in physiological regulation that are associated with an impairment in exercise performance and functional capacity.
Cardiovascular diseases are associated with a profound impairment in both submaximal and peak exercise performances. Slowed V O 2 kinetics have been well documented in patients with cardiovascular diseases that affect the central ''cardiac'' component of V O 2 kinetics (coronary artery disease and cyanotic congenital heart disease) as well as in disease that exhibits both central and skeletal muscle defects (congestive heart failure) (2, 8, 13, 24, 26, 34, 35, 38) . These observations are consistent with the concept that an impaired cardiac output response to exercise limits O 2 delivery to skeletal muscle, resulting in a slower response of V O 2 to any externally imposed work demand. This is in contrast to healthy subjects whose V O 2 kinetics are limited by either a maldistribution of blood flow to the working tissues or inertia of oxidative enzyme activities (6, 15) .
In patients with peripheral arterial disease (PAD), arterial occlusions in the lower extremity limit peripheral blood flow; this results in impaired functional walking ability (17, 28) . Patients with claudication typically have adequate resting blood flow to maintain tissue viability. However, with walking exercise, the inadequate delivery of O 2 and substrate to match metabolic demand results in muscle ischemia, claudication pain, and alterations in skeletal muscle metabolism (17, 20) . Furthermore, these patients have on average a 50% reduction in peak exercise performance as well as a decreased V O 2 -work rate slope during incremental exercise (16) . These observations suggest that the rate of V O 2 adaptation to an increase in work rate is attenuated in PAD and reflects an attenuation of the dynamic response of V O 2 as well as a defect in oxidative metabolism in meeting energy demands. Potentially, the obstruction of blood flow through the major conduit vessels, alterations in skeletal muscle metabolism associated with PAD, or both, could slow the kinetic response of V O 2 during the transition from rest to exercise. To directly test the hypothesis that PAD is associated with slowed V O 2 kinetics, we measured V O 2 kinetics in patients with unilateral and bilateral PAD, and in healthy, nonsmoking subjects and otherwise healthy controls who smoked. The specific aims of the present study were 1) to determine if V O 2 kinetics were slowed in patients with PAD compared with healthy, age-matched, nonsmoking controls and otherwise healthy smoking controls, 2) to characterize V O 2 kinetics in patients with unilateral PAD vs. bilateral PAD, and 3) to determine whether the hemodynamic severity of PAD could account, in part, for altered V O 2 kinetics.
METHODS
Subjects. Thirty-one subjects were enrolled in this study: eight patients with bilateral PAD; seven patients with unilateral PAD; nine healthy, age-matched, nonsmoking controls; and seven smoking, but otherwise healthy, controls. The study was approved by the University of Colorado Multiple Institutional Review Board, and informed consent was obtained from all subjects.
PAD was confirmed by the measurement of the anklebrachial index (ABI; described below). Patients with PAD were enrolled who had an ABI Յ 0.85 in the worse affected leg (the most symptomatic had the lowest ABI). All PAD patients had claudication, defined as aching in the calf muscles that occurred only with exercise and was completely relieved after 10 min of rest. Patients with bilateral disease exhibited claudication symptoms and decreased ABIs in both legs. Patients with unilateral disease were defined as exhibiting claudication symptoms meeting ABI criteria for PAD in the worse affected leg, and with no claudication symptoms and a normal ABI (Ͼ0.95 at rest) in their less affected leg. All PAD patients were current smokers, with a pack · yr history (packs/ day ϫ no. of yr of smoking) of Ͼ30 yr. Of the 14 PAD patients accepted for study, 7 were taking aspirin, 4 were treated with calcium channel blockers, 3 were treated with diuretics, 2 with lipid-lowering drugs, 2 with angiotensin-converting enzyme inhibitors, and 2 with nitrates. Patients were excluded if they exhibited ischemic rest pain or were exercise limited by symptoms other than PAD (heart failure, pulmonary disease, angina). Patients with diabetes and patients taking medications which may alter exercise responses (i.e., beta blockers) were also excluded (30) .
Nonsmoking control subjects had no chronic medical diseases (by history and a normal physical exam), were taking no medications, and had no cigarette smoking history. Nonsmoking control subjects had no history of claudication, had normal ABIs at rest, and had normal electrocardiograms (ECGs) at rest as well as during and after exercise. Smoking controls were all current smokers with a self-reported history of Ն20 pack · yr, but they were otherwise healthy as defined above. Smoking subjects were included in the study design to aid in discrimination between potential effects of smoking vs. PAD on the time constant of V O 2 kinetics (25, 33) .
Exercise protocol. Subjects were not allowed to smoke within 60 min before the start of any of the exercise testing. After familiarization with the treadmill, all subjects were initially tested with a graded treadmill protocol. Patients with PAD (unilateral and bilateral) performed a graded treadmill test at a constant speed of 2.0 miles/h starting at 0% grade and increasing 2.0% every 2 min until maximal claudication pain occurred (14) . Subjects without PAD (nonsmoking controls and smoking controls) performed a standard Bruce treadmill protocol to maximal effort (10) . All tests were performed on a Quinton 4000 treadmill (Quinton Instruments, Seattle, WA). Heart rate (HR) was measured minuteby-minute by using 12-lead ECG recordings. Blood pressure was monitored by auscultation during every stage of graded exercise.
All subjects performed multiple exercise tests at a constant work rate from rest to 2.0 miles/h, 0% grade on 1 day and at 2.0 miles/h, 4% grade on another day that was separated from the first test by 1 wk. These workloads were chosen because they were well tolerated by all subjects and could be sustained for at least 6 min. These workloads elicited a 450-700 ml/min change in absolute V O 2 from baseline. The exercise at 4% grade corresponded to V O 2 values well below the ventilatory anaerobic threshold (VAT) for the healthy subjects. In patients with PAD, the steady-state V O 2 at 4% grade was below the peak V O 2 (V O 2 peak ) attained during claudicationlimited exercise. The VAT could not be measured in PAD patients, because the incremental tests were terminated due to claudication before attaining gas-exchange criteria for establishing VAT. To minimize intertest variance, subjects were familiarized with the testing protocol on the first day, with six to ten 30-s transitions from rest to exercise. As part of the familiarization, each subject initiated walking on a moving treadmill (2.0 miles/h) with the same foot for each transition; one hand was on the handrail, the other was held at the side. The tests for assessment of V O 2 kinetics consisted of obtaining 3 min of resting data, followed by 6 2 and HR data from the constant workload tests were time interpolated to 1-s intervals. The four tests at each workload were then time aligned and averaged by the superimposition of data files. A five-point filter was used to eliminate aberrant breaths from the average response curve. For each value in a response curve, two values preceding and two values after the value in question were considered in the calculation of an expected datum value. Rejection criteria were defined as a range of acceptable values determined as a percentage of the calculated mean for each time-interpolated interval. Rejection criteria and weighting of each of the five points in the calculation were predetermined before filtering. By using a statistical program [BMDP (1988) , Los Angeles, CA], two mathematical models were employed to fit to the average-response curves by using nonlinear regression techniques. A single-exponential model without a time delay was used to assess the overall V O 2 kinetic response at 2.0 miles/h, 0% grade because the V O 2 response curve was monophasic and no phase 1 was observed. The curve is described by the formula
( 1)
is the resting baseline V O 2 (in ml/min) before exercise, A 1 (in ml/min) is the difference between the baseline value and the new steady state, and (in s) is defined as the time constant representing the rate of increase in V O 2 of the exercise-response curve [equal to time (in s) to 63% of the change in V O 2 from baseline to steady-state exercise]. In contrast to the V O 2 responses at 0% grade, the test at 4% grade resulted in a much larger increase in V O 2 ; thus a phase 1 and 2 component of the curves were observed. Multiexponential mathematical modeling was used to fit the average V O 2 response curves at 2.0 miles/h, 4% grade exercise and was utilized to describe three distinct phases of V O 2 kinetics. (6, 7, 36) . These conditions were not observed in PAD patients at these low work rates (19) . Kinetic V O 2 data were also derived at 4% grade, independent of curve-fit modeling techniques, by the sum of breath-by-breath V O 2 (⌺V O 2 ) over several intervals of exercise (from exercise onset to 60, 90, 120, 180, and 300 s). By using the raw breath-by-breath V O 2 data (B n , in ml/min) and the duration of each breath (D n , in s), ⌺V O 2 was calculated as the milliliters of V O 2 consumed over a selected interval minus the product of resting baseline average (V O 2 x, in ml/min) and the duration of the selected interval in minutes (t int ).
⌺V O 2 was normalized to body weight to minimize the influences of weight on absolute V O 2 requirements during treadmill exercise.
ABI. The ABI was calculated in all subjects before exercise testing. ABIs in patients with PAD and in smoking controls were also obtained 1 min after graded exercise. The postexercise ABIs of nonsmoking control subjects were not measured. While subjects were in the supine position, systolic blood pressure was measured in both arms with a Doppler ultrasonic instrument (model 841, Parks Medical Electronics, Beaverton, OR). The pressures in the dorsalis pedis and posterior tibialis vessels of each ankle were also measured in duplicate. The ratio of ankle-to-brachial systolic pressure was determined by taking the highest arm pressure divided into the higher of the two vessels in each ankle.
Data analysis. The data for all PAD patients (unilateral ϩ bilateral) were combined and compared against the combined control groups (nonsmoking ϩ smoking) for ⌺V O 2 analyses. This was done to increase sample size and to provide better discrimination between differences in the PAD and control groups. All other analyses were made by using the means from each of the four separate groups. Between-subject analysis of variance was used to test for differences between groups at baseline. Paired differences were described by using Tukey-Kramer post hoc tests. Paired t-tests were used to compare changes within group means. The alpha level was set to 0.05 for statistical significance. Data are presented as means Ϯ SD for each group.
RESULTS

Subject characteristics.
Patients with PAD and control groups were similar in age and weight (Table 1) . Pack · yr of cigarette use did not significantly differ between the smoking control, unilateral PAD, or bilateral PAD groups but differed from the values observed for the nonsmoking control group (P Ͻ 0.05). ABIs differentiated PAD patients with unilateral disease from those with bilateral disease. The resting ABI in the less affected leg of unilateral PAD patients was similar to the resting ABI of nonsmoking controls and smoking controls. However, the resting ABI in the worse affected leg of unilateral patients was compa- rable to the resting ABI values observed in both legs of bilateral PAD patients. After peak exercise, ABIs decreased in the worse affected legs of unilateral PAD patients by 44% and in both legs of bilateral PAD patients (34% in the worse affected leg, 23% in the less affected leg; all P Ͻ 0.05 vs. rest, by paired t-tests). No decrease in postexercise ABI was observed in the smoking control group or in the less affected leg of unilateral PAD patients after peak exercise.
Peak exercise performance. Unilateral and bilateral PAD patients attained a lower claudication limited V O 2 peak (51 and 55%, respectively), lower HR peak (23 and 31%, respectively), and lower RER peak values (20 and 18%, respectively) compared with the combined control subjects (Table 2 ; P Ͻ 0.05 for each PAD group vs. Control). No differences in peak exercise performance variables were observed between the nonsmoking and smoking control subjects or between the unilateral and bilateral PAD groups.
V O 2 kinetics, 0% grade. Resting V O 2 was comparable between all groups before exercise ( Table 3) . The overall V O 2 kinetic responses of the unilateral and bilateral PAD groups at 0% grade were monoexponential (phase 2) and demonstrated a slowed kinetic response compared with the nonsmoking and smoking control groups (Table 3 ; P Ͻ 0.05). The change in V O 2 from rest to steady state (A 1 ) was also similar between groups.
There were no differences between the kinetic responses of the nonsmoking and the smoking control groups, all of which were monoexponential.
V O 2 kinetics, 4% grade. There were no differences in resting V O 2 between groups before exercise at 4% grade. Phase 1 kinetic parameters ( 0 , A 0 ) were not different between groups (Table 4 ). The time delay (TD 1 ) until the beginning of phase 2 was comparable between all groups. The phase 2 time constant ( 1 ) was similar between the unilateral and bilateral PAD groups (see individual data points in Fig. 2 ), but a significant slowing of the phase 2 time constant was observed in the unilateral and bilateral PAD patients compared with nonsmoking and smoking control subjects (P Ͻ 0.05 for PAD groups vs. combined control groups). The amplitude of phase 2 (A 1 ) was not different between the PAD and control groups. Kinetic parameters did not differ between nonsmoking and smoking control groups. Under the exercise protocols that were used, steady-state exercise conditions were confirmed by a plateau of the V O 2 response and the absence of a phase 3 exponential component of the curve fit for any subject in any group. Values are means Ϯ SD; n, no. of subjects. V O 2 peak , peak O 2 uptake; HR peak , peak heart rate; RER peak , peak respiratory exchange ratio. * Values in PAD groups less than that in individual control groups, P Ͻ 0.05. Table 5 ). Measures from exercise onset to 180 and 300 s did not differ between the PAD patient population and the combined control subjects.
HR responses. Before exercise at 0% grade, resting HRs were comparable between the smoking controls and the unilateral and bilateral PAD patients (Table 6 ), but resting HRs of nonsmoking controls were lower compared with the other three groups (P Ͻ 0.05). HR kinetic analyses for 0 and 4% grades were attempted by using monoexponential curve-fitting techniques. However, the exercise-response curves for HR were neither exponential nor linear and could not be fit reliably by using these methods. Therefore, time constants or mean response times may not have appropriately described the HR response. The mean steady-state HR achieved at the end of the 0% grade exercise was lower in the nonsmoking control group than in the smoking control and in the unilateral and bilateral PAD groups (P Ͻ 0.05). The change in HR from resting to steadystate exercise (⌬HR) was greater in the unilateral and bilateral PAD groups compared with nonsmoking or smoking controls (PAD groups vs. control groups, P Ͻ 0.05).
Before exercise at 4% grade, resting HR was elevated in the unilateral PAD group compared with the nonsmoking and smoking controls and the bilateral PAD patients (P Ͻ 0.05). Steady-state HR at the end of exercise was greater in the unilateral PAD group compared with the nonsmoking and smoking control and the bilateral PAD groups (P Ͻ 0.05). The change in HR at 4% grade was greater in the unilateral and bilateral PAD groups than in the nonsmoking and smoking control groups (P Ͻ 0.05).
Determinants of . To determine whether PAD disease severity was related to the kinetic response of V O 2 during exercise, we evaluated whether resting ABI in the worse affected leg of each PAD patient was correlated to phase 2 time constants at 4% grade. No significant correlation was found (r ϭ Ϫ0.025, Fig. 3 ). Additionally, phase 2 time constants at 4% grade were not correlated with V O 2 peak in patients with PAD (r ϭ 0.257). No correlations of phase 2 time constants and V O 2 peak within the combined control groups were observed (r ϭ Ϫ0.11). Between-group correlations were not assessed because of the distinct difference in populations under investigation (diseased vs. nondiseased) and the possibility of autocorrelation.
DISCUSSION
The present study demonstrates that during constantload treadmill exercise, the kinetics of V O 2 at the onset of exercise were markedly slowed in patients with PAD compared with control subjects. The impaired V O 2 kinetic responses in PAD patients appeared to be related to the presence of vascular disease but not to the hemodynamic severity, because the prolongation in the V O 2 time constant was not associated with the degree of reduction in ABI or whether one or both legs were affected. Furthermore, the V O 2 kinetic impair- Values are means Ϯ SD; no. of subjects in parentheses. ⌺ V O 2 was calculated from onset of exercise (time 0) to specified duration (in s). * Values in PAD groups different from that of individual control groups, P Ͻ 0.05. Values are means Ϯ SD in beats/min; n, no. of subjects. Baseline, resting HR before exercise onset; steady state, steady-state HR at end of exercise; ⌬HR, change in HR from exercise onset to steady state. Baseline and steady-state HR were lower in nonsmoking control group than in other 3 groups during exercise at 0% grade. HR response for exercise at 0% grade was greater in PAD patients than in control subjects. Baseline and steady-state HR were elevated in unilateral PAD patients compared with other 3 groups. HR response to exercise at 4% grade was greater in PAD patients than in control subjects. * Values for individual group different from other 3 groups P Ͻ 0.05. † Value for PAD different from individual control groups, P Ͻ 0.05. http://jap.physiology.org/ ment in PAD could not be explained by phase 1 kinetic differences, reduced HR responses, or current smoking status. This suggests that neither central cardiac factors nor smoking status could account for the marked slowing of the phase 2 time constant observed in patients with PAD.
Typically, to eliminate weight-bearing influences and allow accurate measures of work rate, cycle exercise has been used to determine V O 2 kinetics. Although less optimal than cycle exercise, treadmill exercise was used in the present study to assess the V O 2 kinetics, because walking is the activity that produces the claudication pain observed in patients with PAD. Differences in body weight between groups were not significant and, therefore, were not expected to confound V O 2 kinetic responses. In the present study, neither the total change in V O 2 from resting to steady state at 0% grade (A 1 ) and 4% grade (A 0 ϩ A 1 ) nor the absolute steady-state V O 2 achieved was different between groups. Therefore, the actual work rate and walking efficiency appeared to be similar between groups. The exponential curve fitting was influenced neither by differences in steady-state V O 2 between PAD and control groups nor by the presence of a slow component of V O 2 (phase 3). Furthermore, phase 2 V O 2 kinetics have been shown to be workload independent during cycling exercise at workloads below the lactate threshold (6) . An exponential phase 3 V O 2 kinetic response (slow component) was not observed in any subject during either 0 or 4% grade exercise testing. The absence of a slow component was due to the low level of walking exercise (sub-VAT) and was corroborated by RER values well below 1.00. Although no direct measures of blood lactate concentration were made, previous studies have reported only small increases in systemic lactate levels, even at peak claudication-limited exercise in PAD patients (18, 20) . These observations support the finding in the present study that lactate accumulation and the presence of a phase 3 component of V O 2 are not likely a significant contributor to the slowed kinetics.
Kinetic responses. Phase 1 V O 2 kinetics at 4% grade (representing the cardiac component of V O 2 kinetics) were not different, as assessed by either the time constant ( 0 ) or change in V O 2 (A 0 ) between the PAD and control groups. However, a significantly greater dynamic HR response from rest to steady state (⌬HR) was apparent in the PAD groups compared with the control groups. This could reflect greater cardiac sympathetic stimulation in PAD patients compared with controls. Importantly, a defect in the central cardiac component of the V O 2 kinetic response is possible, although the present data suggest that this may be unlikely.
The time delays of V O 2 (TD 1 ) observed in the present study are longer compared with values observed during measurements made during cycling exercise (6, 7, 31, 36) . Multiexponential modeling with time delays of human V O 2 kinetics has not been previously described during low-level walking exercise. Potentially, the mode of exercise (treadmill walking vs. cycling), exercise intensity, or physiological changes associated with aging (such as alterations in vascular conductance) may elicit an exercise V O 2 response profile that is different from that observed for cycle exercise.
Phase 2 V O 2 kinetic time constants were notably slowed in patients with PAD during treadmill walking at 4% grade. These observations are consistent with the findings of a reduced V O 2 -work rate relationship during incremental cycle exercise in patients with PAD compared with normal controls (16) The data in the present study revealed no differences in time constants () between the unilateral and bilateral PAD groups, despite substantially different quantitative amounts of total lower extremity flow limitation. Furthermore, there was no correlation between worst affected leg ABI and tau in unilateral and bilateral PAD patients. This implies that hemodynamic disease severity (ABI) could not predict the degree of V O 2 kinetic impairment.
Limited peripheral blood flow may only partially account for the slowing of the time constant during phase 2. A second contributor to phase 2 V O 2 kinetics is the responses intrinsic to the exercising muscle. The transition from rest to a fixed workload requires an enhanced production of ATP to meet an elevated ATP requirement. Immediately after the onset of exercise, this energy demand is met by preformed ATP, and the rapid conversion of creatine phosphate (CrP) to ATP. Neither of these energy sources requires the catabolism of substrates or the consumption of O 2 . However, the stores of these high-energy phosphates can only support exercise for brief periods. As ATP and CrP are consumed, the free ADP concentration in muscle increases. Although the regulation of mitochondrial respiration in muscle is complex, the ADP concentration is a potential major control point for stimulating V O 2 . Thus mitochondrial respiration can be described as a function of ADP concentration in vivo (23, 37) . As ADP accumulates with the onset of exercise, mitochondrial O 2 consumption (and hence ATP production) increases until the ADP level sustains an ATP production that matches the ATP demands of the imposed workload. The time constant for the accumulation of ADP in muscle can be equated with the respiratory V O 2 kinetics (5). Therefore, anything that alters the ADP vs. mitochondrial respiration relationship will alter the kinetics of V O 2 . This concept has been observed by the http://jap.physiology.org/ improvement of V O 2 kinetics in older and younger subjects after training and has been validated in patients with mitochondrial myopathies by using 31 Pnuclear magnetic resonance spectroscopy (4, 23, 31) .
Although peripheral blood flow at rest is normal in PAD patients, there is considerable evidence that skeletal muscle metabolic regulation is altered, secondary to the sequellae of muscle ischemia with exercise (9). For example, skeletal muscle in patients with PAD has a 19-36% increase in expression of mitochondrial enzymes, accumulation of oxidative intermediates, and evidence of acquired mitochondrial DNA injury (8a, 11, 12, 18, 21, 23, 32) . These metabolic changes appear to be relevant, because they correlate with patients' functional performance, in contrast to lack of correlation of hemodynamic measurements (1, 20, 29) . Importantly, the ADP vs. mitochondrial respiration relationship is altered in PAD, and more ADP is required than is needed by control subjects to sustain a given level of mitochondrial function. The present demonstration of slowed respiratory V O 2 kinetics in patients with PAD is in complete concordance with the 31 P-nuclear magnetic resonance spectroscopy of Kemp et al. (22) . These data suggest that altered muscle mitochondrial function may contribute to the delayed V O 2 kinetic response, although a detraining effect may present an alternate contributor to the slowed kinetic response in PAD patients. Taken together, these data support the hypothesis that PAD is associated with an alteration in the ADP vs. mitochondrial respiration relationship that potentially results from an acquired mitochondrial myopathy and that strategies to improve metabolic function may be an important therapeutic target (9) .
⌺V O 2 . ⌺V O 2 was used to evaluate 4% grade V O 2 kinetics in a manner independent of curve-fit modeling techniques. This measure of V O 2 kinetics revealed differences between the PAD groups and the combined control groups from exercise onset to 60, 90, and 120 s but not from onset to 180 and 300 s. The loss of discrimination of ⌺V O 2 at 180-and 300-s time intervals suggests that the kinetic response is not well described by time intervals beyond 120 s of exercise. Importantly, ⌺V O 2 can differentiate between diseased and nondiseased patients over the early portions of an exercise transition and can confirm curve-fit analyses of the slowed V O 2 kinetic response in PAD.
Effects of smoking. Because most PAD patients are present or former cigarette smokers, a control group of healthy smoking subjects was included to address the impact of smoking status and pack · yr on the time constant of V O 2 kinetics. Smoking status and pack · yr history may have influenced the time constant of V O 2 kinetics, either through an acute impairment in O 2 -carrying capacity by formation of carboxyhemoglobin or through systemic changes in O 2 utilization caused by chronic cigarette use (25, 33) . However, in smoking control subjects, pack · yr and smoking status were not associated with slowing of the V O 2 time constants compared with nonsmoking controls. Therefore, the impairment in V O 2 kinetics observed in PAD patients was not a direct function of smoking status or pack · yr history.
Summary. The present data demonstrate that the V O 2 kinetic responses to low-level, constant-load treadmill exercise are slowed in patients with PAD. Further research will be necessary to definitively assess whether peripheral flow limitations or changes in the regulation of skeletal muscle oxidative function, or both, are responsible for the observed response in patients with PAD.
